Idarucizumab (dabigatran etexilate mesylate) Antibody, Monoclonal
| Code | Size | Price |
|---|
| PSI-10-593-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: Fab-G1-kappa
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Documents
Further Information
Additional Names:
aDabi-Fab,anti-dabigatran,antidote for dabigatran
Background:
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin use, etc).Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations. Its use is associated with immediate, fully and sustained reversal of the anticoagulant effects of dabigatran.Idarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Humanized / dabigatran etexilate mesylate [Drug]
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.